Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Head-to-head comparison of Epitalon and Humanin — mechanism, side effects, legal status, and pricing.
Epitalon (also Epithalon, AEDG) is a synthetic tetrapeptide (Ala-Glu-Asp-Gly) developed by Vladimir Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology as a synthetic analog of the bovine pineal extract Epithalamin. It is a research-only bioregulator — not FDA-approved and not included in any major Western clinical guideline.
Epitalon
Humanin
Category
Legal Status
Mechanism
Half-life
Side Effects
COA-verified vendors · trust score ≥70 required · single-vial price — bulk/bundle deals may be lower
Epitalon
Humanin
COA corpus from Disclosed Labs — independently tested batches only.
Epitalon
87
COAs
99.3%
Avg purity
14
Labs
Humanin
3
COAs
99.5%
Avg purity
2
Labs
The evidence base is dominated by the Khavinson group. A 2003 paper in Bulletin of Experimental Biology and Medicine (Khavinson, Bondarev, Butyugov; PMID 12937682) reported telomerase activation and telomere elongation in cultured human fetal fibroblasts. Additional Khavinson-group papers and reviews (e.g. 'Peptides and Ageing,' PMID 12374906) describe melatonin-rhythm normalization and claimed geroprotective effects in elderly Russian patients treated with epithalamin or epitalon in open-label / small-cohort studies over 6–12 year follow-up. These clinical studies have significant methodological limitations (open-label design, single-center, limited controls) and have NOT been independently replicated in rigorous Western controlled trials. There are no Phase 2/3 trials, no FDA approval, and no inclusion in Western clinical guidelines. Grey-market dosing of 5–10 mg SubQ daily for 10–20 day cycles, 1–2 times per year, is not clinically validated for any endpoint.
Key references
Hashimoto et al. (2001) discovered humanin through functional screening for neuroprotective factors against amyloid-beta toxicity. Yen et al. characterized the S14G-Humanin analog (HNG) as 1000x more potent. Muzumdar et al. demonstrated that humanin improves insulin sensitivity and reduces visceral fat in animal models. Circulating humanin levels decline with age and correlate inversely with Alzheimer's biomarkers. Cohen et al. showed humanin's role in the GH/IGF-1 axis through IGFBP-3 interaction. No human clinical trials have been conducted — all dosing is extrapolated from preclinical data.
Key references
Epitalon (Cosmetic) and Humanin (Cognitive) are in different categories and target different biological pathways. This is a common pattern in multi-compound research protocols. Researchers should monitor the biomarkers from both profiles and watch for interactions listed in each compound’s contraindications. Consult a licensed healthcare provider before combining any research compounds.
This platform provides informational tools only, not medical advice. This comparison is for educational purposes only. Consult a licensed provider.
Contraindications
Lab Testing
Disclosed Labs